This study focuses on using a medicine called Difluoromethylornithine (DFMO) for patients with a type of cancer called neuroblastoma who are in remission. Neuroblastoma is a cancer that mostly affects young children and starts in certain nerve cells. The study aims to see if DFMO can help prevent the cancer from coming back. The treatment involves taking the medicine by mouth twice a day for 730 days, which is 2 years.

To join this study, patients must have had neuroblastoma and be in complete remission, meaning no sign of the disease. They must have completed previous treatments like chemotherapy. Patients should have good organ function and be able to follow study rules.

• The study lasts for 2 years and requires taking medicine daily.
• Participants must have completed prior treatments and be in remission.
• Participants need to have regular check-ups to ensure they meet health requirements.

It's important for patients to fully understand the study requirements and ensure they can attend all necessary appointments and tests. Written consent is required before joining the study.